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Errors were identified in the Abstract of the published article.

The correct wording is as follow with changes denoted in bold font:

Abstract {#acn3340-sec-0002}
========

**Objectives:** In this study, we address a gap in knowledge regarding the therapeutic potential of acute treatment with a glucagon‐like peptide‐1 (GLP‐1) receptor agonist after severe **traumatic brain injury (TBI)**. Moreover, it remains still unknown whether GLP‐1 treatment activates the protective, anti‐neurodegenerative cAMP response element binding protein (CREB) pathway in the brain in vivo, and whether activation leads to observable increases in protective, anti‐neurodegenerative proteins. Finally, we report the first use of a highly sensitive in vivo imaging agent, **L‐012**, to assess reactive species generation after **TBI**. **Methods: TBI** was induced with a stereotactic cryo‐lesion in mice and thereafter treated with vehicle, liraglutide, or liraglutide + GLP‐1 receptor antagonist, **exendin 9‐39**. A therapeutic window was established and lesion size post‐trauma was determined. Reactive oxygen species were visualized in vivo and quantified directly ex vivo. Hematological analysis was performed over time. Necrosis and apoptosis **signaling**, neuroinflammation **via interleukin‐6 (IL‐6) and blood‐brain barrier (BBB) breakdown** were assessed over time. CREB activation and CREB‐regulated cytoprotective proteins **brain‐derived neurotrophic factor (BDNF), neuroglobin (Ngb), peroxisome proliferator‐activated receptor gamma coactivator 1‐** ***α*** **(PGC‐1a) and b‐cell lymphoma‐2 protein (Bcl‐2)** were assessed over time. **Results:** Lira treatment reduced lesion size by ∼50% through the GLP‐1 receptor. Reactive species generation was reduced by ∼40‐60%. **Lira‐treated animals post‐TBI maintained necrotic and** apoptotic tone similar to **healthy** sham **animals**. Phosphorylation of CREB was markedly increased by Lira in a GLP‐1 receptor‐dependent manner. CREB‐regulated cytoprotective and anti‐neurodegenerative proteins increased with Lira‐driven CREB activation. **Interpretation:** These results show that Lira has potent effects after experimental trauma in mice and thus should be considered a candidate for critical care intervention post‐**TBI**. Moreover, activation of CREB in the brain by Lira ‐ described **here** for the first time **in vivo -- is** dependent on pathology **and** should be investigated further as a potential mechanism of action in neurodegenerative disorders.
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